IFNA2 and autoimmune disease: The initial use of IFN-λ in the treatment of viral infections has revealed advantages over the use of IFN-α2a and IFN-α2b, which have been associated with adverse effects such as fatigue, neurologic signs, autoimmune diseases (75), and proinflammatory effects on immune cells in the respiratory tract (52, 53, 76).